Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Gastrointestinal Issues (Most Common) 70% users mild gastrointestinal symptoms initial weeks
The shortage has created new access barriers for patients previously using or wishing to initiate these products for glycemic management, weight loss, and/or cardiovascular risk reduction
Retatrutides Phase 2 data demonstrating 24.2% mean body weight reduction approaches bariatric surgery outcomes without surgical risk
Make sure to maintain a balanced diet and skincare routine for optimal results
US$ 28.67
US$ 20.08
US$ 27.18
